NSG 5140 ADVANCED
PATHOPHARMACOLOGY FINAL EXAM
2026/2027
1. A patient with chronic kidney disease exhibits a decreased response to a highly protein-
bound drug. Which physiological change explains this phenomenon?
A. Increased serum albumin levels
B. Decreased free fraction of the drug
C. Increased hepatic metabolism of the drug
D. Decreased protein binding due to competitive displacement by metabolic wastes
Answer: D
Conceptual Explanation: In chronic kidney disease, metabolic waste products can
accumulate and competitively displace drugs from albumin binding sites, increasing the
free (active) fraction of the drug.
2. Which pharmacokinetic parameter is most significantly altered in a patient with a large
volume of distribution (Vd) for a specific drug?
A. First-pass metabolism
B. Rate of absorption
,C. Bioavailability
D. Plasma concentration of the drug
Answer: D
Conceptual Explanation: A large Vd indicates that the drug is extensively distributed into
tissues, which results in a lower plasma concentration of the drug.
3. Sacubitril/Valsartan (Entresto) is used in HFrEF. What is the specific mechanism of
Sacubitril?
A. Inhibition of neprilysin to increase natriuretic peptides
B. Inhibition of the AT1 receptor
C. Direct stimulation of guanylate cyclase
D. Antagonism of aldosterone receptors
Answer: A
Conceptual Explanation: Sacubitril is a neprilysin inhibitor, which prevents the
breakdown of natriuretic peptides, leading to vasodilation and natriuresis.
4. Which of the following describes ‘First-Order’ kinetics?
A. A constant amount of drug is eliminated per unit of time
B. The rate of elimination is proportional to the drug concentration
C. The elimination process is saturated
, D. The half-life increases as the concentration decreases
Answer: B
Conceptual Explanation: In first-order kinetics, the rate of drug elimination is directly
proportional to the plasma concentration, meaning a constant percentage is cleared over
time.
5. A patient taking Phenytoin (a CYP450 inducer) starts a new medication that is a CYP450
substrate. What is the likely result?
A. Increased therapeutic effect of the new medication
B. No change in the new medication’s levels
C. Toxicity of the new medication
D. Decreased therapeutic effect of the new medication
Answer: D
Conceptual Explanation: CYP450 inducers increase the metabolism of substrate drugs,
leading to lower plasma levels and reduced therapeutic efficacy.
6. Which antiarrhythmic drug is associated with pulmonary fibrosis and thyroid dysfunction?
A. Lidocaine
B. Verapamil
C. Procainamide
D. Amiodarone
PATHOPHARMACOLOGY FINAL EXAM
2026/2027
1. A patient with chronic kidney disease exhibits a decreased response to a highly protein-
bound drug. Which physiological change explains this phenomenon?
A. Increased serum albumin levels
B. Decreased free fraction of the drug
C. Increased hepatic metabolism of the drug
D. Decreased protein binding due to competitive displacement by metabolic wastes
Answer: D
Conceptual Explanation: In chronic kidney disease, metabolic waste products can
accumulate and competitively displace drugs from albumin binding sites, increasing the
free (active) fraction of the drug.
2. Which pharmacokinetic parameter is most significantly altered in a patient with a large
volume of distribution (Vd) for a specific drug?
A. First-pass metabolism
B. Rate of absorption
,C. Bioavailability
D. Plasma concentration of the drug
Answer: D
Conceptual Explanation: A large Vd indicates that the drug is extensively distributed into
tissues, which results in a lower plasma concentration of the drug.
3. Sacubitril/Valsartan (Entresto) is used in HFrEF. What is the specific mechanism of
Sacubitril?
A. Inhibition of neprilysin to increase natriuretic peptides
B. Inhibition of the AT1 receptor
C. Direct stimulation of guanylate cyclase
D. Antagonism of aldosterone receptors
Answer: A
Conceptual Explanation: Sacubitril is a neprilysin inhibitor, which prevents the
breakdown of natriuretic peptides, leading to vasodilation and natriuresis.
4. Which of the following describes ‘First-Order’ kinetics?
A. A constant amount of drug is eliminated per unit of time
B. The rate of elimination is proportional to the drug concentration
C. The elimination process is saturated
, D. The half-life increases as the concentration decreases
Answer: B
Conceptual Explanation: In first-order kinetics, the rate of drug elimination is directly
proportional to the plasma concentration, meaning a constant percentage is cleared over
time.
5. A patient taking Phenytoin (a CYP450 inducer) starts a new medication that is a CYP450
substrate. What is the likely result?
A. Increased therapeutic effect of the new medication
B. No change in the new medication’s levels
C. Toxicity of the new medication
D. Decreased therapeutic effect of the new medication
Answer: D
Conceptual Explanation: CYP450 inducers increase the metabolism of substrate drugs,
leading to lower plasma levels and reduced therapeutic efficacy.
6. Which antiarrhythmic drug is associated with pulmonary fibrosis and thyroid dysfunction?
A. Lidocaine
B. Verapamil
C. Procainamide
D. Amiodarone
